Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Clinical trial NCT05476380 · UNKNOWN
Trial details
- NCT number
- NCT05476380
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-19
- Primary completion
- 2022-12-01
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.